Corient Private Wealth
IOVA icon

Corient Private Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

Corient Private Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
+55,275
New +$210K ﹤0.01% 2728
2024
Q2 		– Sell
-112,262
Closed -$1.66M – 2350
2024
Q1 		$1.66M Sell
112,262
-254,738
-69% -$2.96M ﹤0.01% 1110
2023
Q4 		$2.98M Buy
367,000
+247,199
+206% +$1.29M 0.01% 849
2023
Q3 		$545K Sell
119,801
-91,837
-43% -$600K ﹤0.01% 1445
2023
Q2 		$1.49M Buy
+211,638
New +$1.51M ﹤0.01% 1005

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Corient Private Wealth's IOVA Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 55,275 shares worth $230K. The stake represents ﹤0.01% of the portfolio and ranks #2728 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in IOVA as recently as Q1 2024.

Corient Private Wealth first reported a position in IOVA in Q2 2023 and has held it in 5 quarters since. The position peaked at $2.98M in Q4 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Corient Private Wealth held 55,275 shares of Iovance Biotherapeutics worth $230K as of Q2 2026.
  • Iovance Biotherapeutics was a new Corient Private Wealth position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2728 holding.
  • Corient Private Wealth first reported a position in Iovance Biotherapeutics in Q2 2023 and has held it in 5 quarters since.
  • Corient Private Wealth's Iovance Biotherapeutics position peaked at $2.98M in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.